Top news of the week: 08.04.2021.
Companies And Industries
Bluebird's chief medical officer flies the nest to gene writing biotech Tessera
After nabbing $230 million at the start of the year, “gene writing” biotech Tessera Therapeutics has boosted its management and research team, including poaching bluebird bio’s chief ...
HIV Research is at an Inflection Point, Offering Hope for a Cure
Recent advances are giving researchers hope that a functional cure or possibly even complete eradication of the virus is possible.
BioSpace Movers & Shakers: Precigen, Amylyx, BeiGene and More
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Novavax adds blinded crossover arms to COVID-19 vaccine trials
Novavax has added crossover arms to late-phase clinical trials of its COVID-19 vaccine. The action will enable participants in the placebo cohorts of the original trials to get vaccinated ...
Scholar Rock eyes phase 3 after confirming effects of SMA drug
Scholar Rock has reported 12-month data on spinal muscular atrophy candidate apitegromab. The readout is in line with the six-month data drop that sent Scholar Rock’s stock price soaring in ...
Book traversal links for The top 10 pharma R&D budgets in 2020
While 2020 was a year to forget for almost the entire globe, the R&D engine of pharma roared to life in a never-before-seen way by creating new drugs, vaccines and tests for the pandemic ...
Brooklyn ImmunoTherapeutics, Overland ADCT BioPharma Name New CEOs
The biopharmaceutical industry saw two CEO appointments made today, including Howard J. Federoff, M.D., Ph.D., to Brooklyn ImmunoTherapeutics and Eric Koo to Overland ADCT BioPharma.
The Next Generation of Cell Factories for Viral Vector Production
Although the industry still relies on transient transfection, due to the difficulty of creating stable production cell lines, a shift from adherent to suspension culture is underway.